BPC-157

The most-discussed recovery peptide, built on decades of animal work and very little human data.

Evidence: ELab & animal what's this?
Grade E for efficacy. Hundreds of animal studies, and a handful of tiny human pilots.
Also known as: Body Protection Compound-157 · Bepecin · PL 14736
Class: Synthetic 15-amino-acid peptide (GEPPPGKPADDAGLV) modelled on a protein in gastric juice

The 30-second version

WhatA short, unusually acid-stable peptide first studied for protecting the stomach lining.

Why people use itTo speed up healing of tendons, ligaments, muscle and the gut.

The honest catchAlmost every result comes from rats. There is no controlled human trial of efficacy.

What it is

BPC-157 is a chain of fifteen amino acids. Researchers in Zagreb modelled it on part of a larger protective protein found in human gastric juice, which explains its unusual trait: it stays intact in stomach acid, where most peptides would be digested within minutes. The literature often calls it a stable gastric pentadecapeptide for that reason.

Work on it began with the gut, protecting the stomach and intestinal lining against damage. Over thirty years the focus has widened to tendon, ligament, muscle, bone and nerve. That body of work made it the best-known "healing peptide" in fitness circles. It is not approved as a medicine in any country.

How it works

BPC-157 doesn't act on one receptor. In animal and cell studies it touches several repair pathways at once, and all of them lead to the same place: getting blood, cells and collagen to damaged tissue.

Arrives at injured tissue, given by injection or by mouth.

New vessels. Raises VEGF and activates VEGFR2, so the area builds a fresh blood supply (angiogenesis).

Cells move in. Switches on FAK–paxillin signalling, which helps repair cells attach, migrate and divide.

Rebuild. More type I collagen, and tendon cells carry more growth-hormone receptors.

Calm. Inflammatory signals drop and nitric-oxide balance improves, which protects the tissue.

There is also a nervous-system thread. Rodent studies show effects on dopamine and serotonin signalling, which researchers link back to its gut origin through the gut–brain axis. That work is early, and nobody has confirmed it in people.

What the research shows

In people. This is the weak point. A 2025 systematic review in HSS Journal screened 544 papers and kept 36. Thirty-five were preclinical. One was clinical: a small retrospective series of knee injections, in which 7 of 12 patients reported pain relief lasting more than six months¹. The rest of the human record is a two-person intravenous safety pilot (doses up to 20 mg were tolerated and cleared from blood within a day) and a small bladder-instillation study for interstitial cystitis². A Phase I safety trial was registered in 2015 but never published results³.

In animals. This is where BPC-157 is strong. In rats, mice and dogs it consistently improved healing of the Achilles and other tendons, ligaments, muscle and bone, with stronger and better-organised repaired tissue¹. It also protected the gut against anti-inflammatory-drug damage and in colitis models. The results repeat across many injury types, but most come from one research group, and a rat tendon is not a human one.

In the lab. Cell studies support the mechanism above: blood-vessel growth, cell migration, more growth-hormone receptors and more collagen^1,4.

Thirty years of animal studies tell you the idea is worth testing. They don't replace a single good human trial.

Evidence at a glance

Use	Grade	Best evidence	Main gap	Read
Tendon & ligament healing	ELab & animal	Faster, stronger healing across many animal models¹	Almost all rat data	Promising, unproven
Knee & joint pain	DCommunity use	7 of 12 reported relief after a knee injection¹	Tiny, uncontrolled	Weak early signal
Gut protection	ELab & animal	Protected and healed the gut lining in animals	No human trial	Strong in animals
Human safety	BHuman trials	No adverse events in small pilots²	A handful of people	Reassuring, minimal

Dosing: what has actually been reported

Not a recommendation. No human dosing trial exists for BPC-157. The figures below describe what was studied or what circulates in the community, kept apart so you can see how solid each one is. Talk to a qualified clinician before acting on anything here.

Setting	Figure	Route	Grade
Published human pilots	Single knee injection; IV up to 20 mg in a 2-person safety pilot²	Intra-articular / IV	B isolated figures, not a schedule
Clinic off-label	Local injections near the injured site; no standard protocol	Local	C
Community, general	250–500 mcg per day, cycles of 4–8 weeks	Subcutaneous	D
Community, gut	Similar or higher amounts by mouth	Oral	D

Animal doses (roughly 10 ng to 10 µg per kg in rats) don't scale neatly to people, and the community figures don't come from any human dose-finding work. Treat them as context, not as a target.

Preparing & storing

Lyophilised (freeze-dried) BPC-157 is stable at room temperature for a short time, out of light, but long-term storage should be cold. Reconstitute it with bacteriostatic water by running the water down the inside of the vial, then swirl gently rather than shaking. Keep the mixed vial refrigerated at 2–8 °C. Its acid stability is the reason an oral form is plausible at all. See the mixing calculator for the arithmetic.

Reported side effects

Injection-site redness, itch or a small lump (most common)
Mild nausea, more often with oral use
Headache or light-headedness early on
Transient flushing or tiredness
Rare reports of a racing heart. Stop and get assessed if this happens.

These come from pilots and anecdotes. Animal toxicity work found no lethal dose. The bigger unknown is long-term human safety, which has never been studied.

Who should avoid it

Anyone with current or past cancer. Its main effect is growing new blood vessels, and tumours rely on new vessels too. Researchers have argued both sides and the question is unresolved.
Pregnancy and breastfeeding (no data)
Tested athletes: WADA prohibited (S0) since 2022
Anyone on regular medication should get medical input first

Regulatory status checked Oct 2026

Body	Status	Detail
FDA (US)	Not approved	Placed in the compounding "significant safety risk" category, so pharmacies can't compound it. Sold for research use only.
EMA (EU)	Not approved	No marketing authorisation.
CDSCO (India)	Not approved	No approval identified.
WADA	Prohibited	S0 non-approved substance, banned in and out of competition.

The NexGen read

Strong biology, thin human proof

BPC-157 has one of the most consistent animal records of any peptide, and the repair mechanism behind it is well mapped. What it lacks is a controlled human trial, plus long-term safety data and an answer to the question of whether it could feed tumours. Anyone using it is relying on animal data, so keep it away from any cancer history and out of tested sport.

References

Vasireddi N, Hahamyan H, Salata MJ, et al. Emerging use of BPC-157 in orthopaedic sports medicine: a systematic review. HSS J. 2025;21(4):485–495. doi:10.1177/15563316251355551
Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. PMC12446177 (summarises the Lee & Padgett 2021 knee series, the Lee & Burgess 2025 IV pilot and an intravesical study).
ClinicalTrials.gov. Safety and pharmacokinetics of Bepecin (BPC-157) in healthy volunteers. NCT02637284.
From regeneration to analgesia: the role of BPC-157 in tissue repair and pain management. Int J Mol Sci. 2026;27(6):2876.